The Heterogeneous Prognosis Of Patients With Myelodysplastic Syndrome (MDS) And Chromosome 5 Abnormalities: How Does It Relate To The Original Lenalidomide Experience in MDS?

Ítems similars

• Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities
  per: Ravandi, Farhad, et al.
  Publicat: (2009)
• Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers
  per: Naqvi, Kiran, et al.
  Publicat: (2011)
• Significance of Thrombocytopenia in Myelodysplastic Syndromes: Associations and Prognostic Implications
  per: Ameri, Ali Al, et al.
  Publicat: (2011)
• A Phase II Study of Lenalidomide Alone in Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes With Chromosome 5 Abnormalities
  per: Chen, Yiming, et al.
  Publicat: (2012)
• Predicting Survival of Patients with Hypocellular Myelodysplastic Syndrome: Development of a Disease Specific Prognostic Score System
  per: Tong, Wei-Gang, et al.
  Publicat: (2012)